卡泊芬净治疗侵袭性真菌疾病的药物经济学综述

• 药物经济学 • 上一篇

卡泊芬净治疗侵袭性真菌疾病的药物经济学综述

郭祖德,魏艳,陈英耀

复旦大学,复旦大学,复旦大学

收稿日期:2016-10-12 修回日期:2016-11-25 出版日期:2016-12-25 发布日期:2016-12-26

Reviews on Pharmacoeconomics Evaluation of Caspofungin in the Treatment of Invasive Fungal Disease

Fudan University,,

Received:2016-10-12 Revised:2016-11-25 Online:2016-12-25 Published:2016-12-26

摘要/Abstract

摘要： 目的：介绍卡泊芬净在治疗侵袭性真菌疾病的经济学评价现状。方法：检索中文和外文数据库，并进行归纳和分析。结果：共检索出14篇英文文献，研究结果显示卡泊芬净在各国粒缺发热患者的经验性治疗中具有较好的成本效果。结论：由于各国卫生国情有所不同，各国研究结果是否适用于我国还有待进一步研究。

Abstract: Objective：A review was conducted to introduce the pharmacoeconomics evaluation of caspofungin in the treatment of invasive fungal disease. Methods：Literatures were searched and analyzed in the database of CNKI， CBM， VIP， PubMed， Web of Knowledge and EMBASE. Results：14papers were included in this research. Studies showed that caspofungin could be cost effectiveness or cost-saving for empiric therapy. Conclusion： A further research should be performed to evaluate the pharmacoeconomics of caspofungin based on the health system in China.

郭祖德,魏艳,陈英耀. 卡泊芬净治疗侵袭性真菌疾病的药物经济学综述[J]. .

参考文献

1.中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第四次修订版)[J].中华内科杂志,2013,52(8):704-709
2.Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, et al.actors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008;47:1176–84
3.Guo F, Yang Y, Kang Y, et al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study[J]. Journal of Antimicrobial Chemotherapy, 2013, 68(7): 1660-1668.
4.Wingard J, Leather H, Wood C, Gerth W, Lupinacci R, Berger M, et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am J Health Syst Pharm 2007;64:637–43.
5.周晓明.抗真菌药物及其临床应用进展[J].中国药业,2014,(14):117-119
6.刘秀书,邹爱英.棘白菌素类抗真菌药临床应用研究进展[J].天津药学,2014,26(6):70-72
7.林东昉,吴菊芳,韩明哲等.卡泊芬净经验性治疗粒细胞减少伴持续发热患者的安全性、耐受性和疗效的非对照、开放、多中心临床研究[J].中国感染与化疗杂志,2008,8(5):347-3548.骆雪萍,夏炳杰,叶宁等.卡泊芬净治疗重症患者侵袭性真菌感染疗效及安全性评价[J].中华医院感染学杂志,2011,21(16):3480-3482
9.Wingard J R, Wood C A, Sullivan E, et al. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis[J]. Clin Ther, 2005,27(6):960-969
10.Golan Y, Wolf M P, Pauker S G, et al. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis[J]. Ann Intern Med, 2005,143(12):857-869
11.Dominguez-Gil A, Martin I, Garcia V M, et al. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain[J]. Clin Drug Investig, 2007,27(3): 197-205.
12.Wingard J R, Leather H L, Wood C A, et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever[J]. Am J Health Syst Pharm, 2007,64(6):637-643
13.Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK[J]. Eur J Haematol, 2007,78(6):532-539
14.Kaskel P, Tuschy S, Wagner A, et al. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting[J]. Annals of hematology, 2008, 87(4): 311-319.
15.Stam W B, Aversa F, Kumar R N, et al. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy[J]. Value Health, 2008,11(5):830-841
16.Sidhu M K, van Engen A K, Kleintjens J, et al. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK[J]. Curr Med Res Opin, 2009, 25(8):2049-2059.
17.Al-Badriyeh D, Liew D, Stewart K, et al. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia[J]. Journal of antimicrobial chemotherapy, 2009, 63(6): 1276-1285.
18.Naik S, Lundberg J, Kumar R, et al. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden[J]. Scand J Infect Dis, 2011,43(6-7):504-514
19.Al-Badriyeh D, Liew D, Stewart K, et al. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia[J]. Mycoses, 2012,55(3):244-256
20.Neoh C F, Liew D, Slavin M A, et al. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis[J]. Intern Med J, 2013,43(6):668-677
21.Turner S J, Senol E, Kara A, et al. Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey[J]. Int J Antimicrob Agents, 2013,42(3):276-280
22.Turner S J, Senol E, Kara A, et al. Cost effectiveness of caspofungin vs. voriconazole for empiric therapy in Turkey[J]. Mycoses, 2014,57(8):489-496
23.Luong M L, Husain S, Rotstein C. Pharmacoeconomic assessment of therapy for invasive aspergillosis[J]. Mycoses, 2013, 56(3): 338-349.